Potential neuroprotective benefits of erythropoietin during experimental hypothermic circulatory arrest.

OBJECTIVE Recent studies have shown that erythropoietin protects neurons from glutamate toxicity and ischemia. This study was performed to evaluate the potential neuroprotective effect of erythropoietin during experimental hypothermic circulatory arrest. METHODS Twenty pigs were randomized to receive intravenously either 500 IU/kg recombinant human erythropoietin or saline before a 75-minute period of hypothermic circulatory arrest at an intracerebral temperature of 18 degrees C. RESULTS After the administration of erythropoietin, its concentration in the cerebrospinal fluid increased 4.5-fold 8 hours after the start of rewarming, whereas it did not increase in control animals. The 7-day survival rate was 60% in the erythropoietin group and 70% in the control group (P = 1.0). No significant differences were observed between the study groups in terms of electroencephalography, behavioral score, and histopathologic score. The erythropoietin group had higher vascular resistance and mean arterial pressure values, lower intracerebral concentrations of glutamate and glycerol, higher brain tissue oxygen tension, and lower apoptotic index. CONCLUSIONS Administration of 500 IU/kg erythropoietin intravenously before hypothermic circulatory arrest was followed by an increased erythropoietin concentration in the cerebrospinal fluid. Although previous studies have demonstrated neuroprotective effects of erythropoietin during brain ischemia, the present study, using a chronic porcine model, failed to show any significant benefit after administration of erythropoietin in terms of mortality or brain histopathology. Lower intracerebral concentrations of glutamate and glycerol, higher brain tissue oxygen tension, and lower apoptotic index observed in the erythropoietin group, however, suggest that a distinct neuroprotective effect of erythropoietin might be achieved at different dosages and timing of administration.

[1]  A. Cerami,et al.  Beyond erythropoiesis: novel applications for recombinant human erythropoietin. , 2001, Seminars in hematology.

[2]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Allegra,et al.  Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. , 2000, European journal of pharmacology.

[5]  F. Tomasello,et al.  In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage. , 2000, European journal of pharmacology.

[6]  S. Juul,et al.  Erythropoietin in the Cerebrospinal Fluid of Neonates Who Sustained CNS Injury , 1999, Pediatric Research.

[7]  S. Orkin,et al.  GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. , 1999, Blood.

[8]  E. Mackenzie,et al.  A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  K. Koshimura,et al.  Effects of Erythropoietin on Neuronal Activity , 1999, Journal of neurochemistry.

[10]  S. Masuda,et al.  Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. , 1998, Biochemical and biophysical research communications.

[11]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Gassmann,et al.  Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. , 1997, Kidney international.

[13]  E. Morishita,et al.  Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death , 1996, Neuroscience.

[14]  A. Dusso,et al.  Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. , 1993, Kidney international.

[15]  F. Nakhoul,et al.  Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. , 1991, The American journal of physiology.

[16]  K. Rahn,et al.  Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. , 1991, Kidney international.

[17]  A. Raine HYPERTENSION, BLOOD VISCOSITY, AND CARDIOVASCULAR MORBIDITY IN RENAL FAILURE: IMPLICATIONS OF ERYTHROPOIETIN THERAPY , 1988, The Lancet.

[18]  K. Aoki,et al.  Characterization and biological effects of recombinant human erythropoietin. , 1986, Immunobiology.

[19]  R. Hoppenstein SPINAL FUSION FOR BACK PAIN AND SCIATICA. , 1965, Lancet.

[20]  J. O'brien,et al.  Identification of a neurotrophic sequence in erythropoietin. , 1998, International journal of molecular medicine.

[21]  D Grillot,et al.  Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. , 1996, Blood.